Galmed Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary
U.S. STOCKS ON THE MOVE-Baidu, Lowe's Companies, Best Buy
U.S. STOCKS ON THE MOVE-Dycom Industries, Crypto stocks, Burlington Stores
Galmed Pharmaceuticals down on delays to lead drug's mid-stage study
Brief: Galmed Announces A Delay In The Initiation Of Its Primary Sclerosing Cholangitis (Psc) Phase 2A Study
Brief: Galmed Announces Allowance Of New Patent For Aramchol For The Treatment Of Pulmonary And Dermal Fibrosis
Brief: Galmed Pharmaceuticals Announces Receipt Of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Ltd expected to post a loss of 34 cents a share - Earnings Preview
Brief: Cvi Investments Reports Passive Stake Of 9.9% In Galmed Pharmaceuticals Ltd. As Of July 14
Brief: Galmed To Employ Onkai's Disruptive Artificial Intelligence (Ai) In Its Planned Phase 2A Clinical Trial In Psc
Brief: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results And Recent Developments
Galmed Pharmaceuticals Ltd expected to post a loss of 10 cents a share - Earnings Preview
Brief: Galmed Announces Initiation Of A Clinical Development Program To Evaluate Aramchol Meglumine For The Treatment Of Primary Sclerosing Cholangitis (Psc)
Galmed Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary
Galmed Pharmaceuticals Ltd expected to post a loss of 15 cents a share - Earnings Preview
Brief: Galmed Announces Issuance Of New Composition Of Matter Patent For Aramchol Meglumine Salt
U.S. STOCKS ON THE MOVE-Galmed, NuScale Power, Primoris
Galmed rises on positive results from NASH drug study
Brief: Galmed Reports Results From The Open-Label Part Of The Armor Study Showing Improvements In Histology, Imaging, And Biomarkers With Aramchol